FULC - Fulcrum Therapeutics GAAP EPS of -$0.38 beats by $0.06 revenue of $0.9M misses by $0.06M
2023-08-03 10:18:52 ET
- Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q2 GAAP EPS of -$0.38 beats by $0.06 .
- Collaboration revenue of $0.9M (-52.6% Y/Y) misses by $0.06M .
- As of June 30, 2023, cash, cash equivalents, and marketable securities were $278.2 million, as compared to $202.9 million as of December 31, 2022.
For further details see:
Fulcrum Therapeutics GAAP EPS of -$0.38 beats by $0.06, revenue of $0.9M misses by $0.06M